VaxInnate Corporation Begins Phase I Clinical Trial to Evaluate H5N1 Vaccine Candidate for Pandemic Avian Flu
6/12/2012 10:18:26 AM
CRANBURY, N.J.--(BUSINESS WIRE)--VaxInnate Corporation today announced that enrollment has commenced in a Phase I clinical trial to evaluate VAX161, its novel H5 vaccine candidate in development for the prevention of pandemic avian influenza or bird flu. VaxInnate is a biotechnology firm pioneering breakthrough technology for developing novel vaccines.
comments powered by